# Development of Therapeutic Products for Antibiotic Resistant Bacteria

> **NIH NIH N01** · VENATORX PHARMACEUTICALS, INC. · 2022 · $7,440,148

## Abstract

To support the advanced development of a promising candidate therapeutics. The research and development activities to be supported will allow the candidate therapeutic product to progress through the product development pathway, and include preclinical and IND enabling development activities, chemistry optimization/development, GMP manufacturing, and clinical safety and efficacy assessment.

## Key facts

- **NIH application ID:** 10630898
- **Project number:** 75N93020C00016-P00003-9999-1
- **Recipient organization:** VENATORX PHARMACEUTICALS, INC.
- **Principal Investigator:** DANIEL PEVEAR
- **Activity code:** N01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $7,440,148
- **Award type:** —
- **Project period:** 2020-07-01 → 2023-05-29

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10630898

## Citation

> US National Institutes of Health, RePORTER application 10630898, Development of Therapeutic Products for Antibiotic Resistant Bacteria (75N93020C00016-P00003-9999-1). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10630898. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*